Ingevity (NGVT) director receives 329 deferred stock units in lieu of board fees

Rhea-AI Filing Summary

Ingevity Corp director Francis David Segal received a grant of 329 vested deferred stock units at $72.28 per unit. These units were issued in lieu of quarterly director fees and increase his directly owned common stock-related position to 6,380 shares.

The deferred stock units will convert into an equal number of Ingevity common shares when his board service ends, under the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Segal Francis David

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	329	$72.28	$24K

Holdings After Transaction: Common Stock — 6,380 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Deferred stock units granted: 329 units Grant price per unit: $72.28 per unit Shares following transaction: 6,380 shares

3 metrics

Deferred stock units granted 329 units Director fee-equity grant on 2026-04-01

Grant price per unit $72.28 per unit Value used for 329 DSUs granted

Shares following transaction 6,380 shares Segal’s direct holdings after the award

Key Terms

deferred stock units, Non-Employee Director Deferred Compensation Plan, 2025 Omnibus Incentive Plan, grant, award, or other acquisition

4 terms

deferred stock units financial

"Represents vested deferred stock units ("DSUs") granted pursuant to the reporting person's election"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

Non-Employee Director Deferred Compensation Plan financial

"pursuant to the Company's Amended and Restated Non-Employee Director Deferred Compensation Plan"

2025 Omnibus Incentive Plan financial

"pursuant to the Company's Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Segal Francis David

(Last) (First) (Middle)

C/O INGEVITY CORPORATION

4920 O'HEAR AVE, SUITE 400

(Street)

NORTH CHARLESTON SOUTH CAROLINA 29405

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ingevity Corp [ NGVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		329(1)	A	$72.28	6,380	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents vested deferred stock units ("DSUs") granted pursuant to the reporting person's election to receive DSUs in lieu of quarterly director fees. These DSUs will settle into an equal number of shares of the Company's Common Stock upon the reporting person's termination of board service pursuant to the Company's Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan.

Remarks:

	Francis David Segal By: Mavis G. Huger as Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ingevity (NGVT) disclose for Francis David Segal?

Ingevity disclosed that director Francis David Segal received 329 vested deferred stock units valued at $72.28 each. The award represents director fees taken in equity instead of cash and is part of routine board compensation, not an open-market stock purchase or sale.

How many Ingevity (NGVT) shares does Francis David Segal hold after this Form 4?

After the reported grant, Francis David Segal beneficially owns 6,380 shares or share-equivalent units of Ingevity common stock directly. This figure reflects his holdings following the 329 deferred stock units granted in lieu of quarterly director fees under company compensation plans.

What are deferred stock units (DSUs) in the Ingevity (NGVT) Form 4 filing?

Deferred stock units are share-equivalent awards credited instead of cash fees, which later settle into actual shares. In this case, Segal’s 329 vested DSUs will convert into the same number of Ingevity common shares when his board service ends, according to company compensation plans.

When will Francis David Segal’s Ingevity (NGVT) deferred stock units convert into shares?

Segal’s 329 deferred stock units will settle into an equal number of Ingevity common shares upon his termination of board service. This timing is defined in the company’s Amended and Restated Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan governing director equity awards.

Is the Ingevity (NGVT) Form 4 transaction a stock purchase on the market?

No, the Form 4 shows a grant of 329 deferred stock units as compensation, not an open-market trade. The units were issued in lieu of quarterly director fees and vest immediately, later converting to Ingevity common stock when Segal’s board service concludes under company plan terms.